Search research articles
Contact Us
Filters
Showing results (201-210 of 228) with videos related to
Page
of 23
Sort By:
Clinical Hematology International
|
August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Chinese Medical Journal
|
May 29, 2025
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Wenting Chen, Jianhua You, Li'e Lin, et al.
Clinical Hematology International
|
May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
The Lancet Regional Health. Western Pacific
|
June 19, 2025
Imaging in plasma cell disorders-consensus recommendations of the Asian myeloma network bone imaging workgroup
Chandramouli Nagarajan, Natasha Fay Anthony, Jens Hillengass, et al.
Frontiers in Oncology
|
May 8, 2023
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
Zhe Zhuang, Ying Tian, Lei Shi, et al.
Journal of Medicinal Chemistry
|
August 16, 2022
Discovery of Novel cccDNA Reducers toward the Cure of Hepatitis B Virus Infection
Dongdong Chen, Xuefei Tan, Wenming Chen, et al.
BMC Medicine
|
April 5, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Lugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.
The Lancet. Haematology
|
April 7, 2023
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
Xiaofan Liu, Hu Zhou, Yu Hu, et al.
American Journal of Hematology
|
April 12, 2014
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study
Kihyun Kim, Jae Hoon Lee, Jin Seok Kim, et al.
BMC Medical Research Methodology
|
May 2, 2024
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)
Naomi Aoki, Pin-Yen Chen, Wenming Chen, et al.
Page
of 23
Search research articles
Search
Showing results (201-210 of 228) with videos related to
Sort By:
Page
of 23
Clinical Hematology International
|
August 11, 2025
Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-Pacific Multiple Myeloma Working Group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
Chinese Medical Journal
|
May 29, 2025
Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
Wenting Chen, Jianhua You, Li'e Lin, et al.
Clinical Hematology International
|
May 8, 2026
Guidelines and consensus for minimal residual disease-adapted therapy in multiple myeloma from the Pan-Pacific multiple myeloma working group
Wenming Chen, Zhen Cai, Chor Sang Chim, et al.
The Lancet Regional Health. Western Pacific
|
June 19, 2025
Imaging in plasma cell disorders-consensus recommendations of the Asian myeloma network bone imaging workgroup
Chandramouli Nagarajan, Natasha Fay Anthony, Jens Hillengass, et al.
Frontiers in Oncology
|
May 8, 2023
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China
Zhe Zhuang, Ying Tian, Lei Shi, et al.
Journal of Medicinal Chemistry
|
August 16, 2022
Discovery of Novel cccDNA Reducers toward the Cure of Hepatitis B Virus Infection
Dongdong Chen, Xuefei Tan, Wenming Chen, et al.
BMC Medicine
|
April 5, 2022
Selinexor plus low-dose dexamethasone in Chinese patients with relapsed/refractory multiple myeloma previously treated with an immunomodulatory agent and a proteasome inhibitor (MARCH): a phase II, single-arm study
Lugui Qiu, Zhongjun Xia, Chengcheng Fu, et al.
The Lancet. Haematology
|
April 7, 2023
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
Xiaofan Liu, Hu Zhou, Yu Hu, et al.
American Journal of Hematology
|
April 12, 2014
Clinical profiles of multiple myeloma in Asia-An Asian Myeloma Network study
Kihyun Kim, Jae Hoon Lee, Jin Seok Kim, et al.
BMC Medical Research Methodology
|
May 2, 2024
The establishment of a multiple myeloma clinical registry in the Asia-Pacific region: The Asia-Pacific Myeloma and Related Diseases Registry (APAC MRDR)
Naomi Aoki, Pin-Yen Chen, Wenming Chen, et al.
Page
of 23